Welcome to our dedicated page for Prenetics news (Ticker: PRE), a resource for investors and traders seeking the latest updates and insights on Prenetics stock.
Prenetics Global Limited (NASDAQ: PRE) generates an active stream of company news centered on its evolution as a health sciences business and the rapid growth of its IM8 premium health and longevity brand. Press releases describe Prenetics as a leading health sciences company focused on redefining the future of health and longevity through IM8, a premium core nutrition platform co-founded with David Beckham and championed by World No. 1 and four-time Grand Slam winner Aryna Sabalenka.
News updates commonly highlight IM8’s growth milestones, including disclosures that the brand reached over $100 million in annualized recurring revenue within roughly 11 months of launch and has been characterized by the company as the fastest-growing supplement brand in industry history. Articles also cover monthly revenue achievements, subscription metrics, and international expansion, reflecting IM8’s role as the centerpiece of Prenetics’ strategy.
Investors following PRE can also expect news on capital allocation and financing activities. Recent announcements include a best efforts public offering of Class A ordinary shares with accompanying warrants, a voluntary warrant exchange program designed to reduce potential dilution and simplify the capital structure, and updates on the company’s Bitcoin treasury strategy. Prenetics has communicated a shift away from new Bitcoin purchases, choosing instead to maintain existing holdings as a treasury reserve while directing new capital exclusively toward IM8.
Another recurring theme in Prenetics news is strategic portfolio optimization. Releases describe the sale of ACT Genomics, the divestiture of Europa Sports Partners, and an ongoing review of other non-core assets such as CircleDNA and the company’s stake in Insighta. These items are presented as part of a broader effort to focus on IM8 and improve operating margins.
News items may also include earnings announcements, conference participation, and insider share purchases by members of the executive leadership team, which are furnished to the SEC on Form 6-K. For readers tracking PRE, this news page provides a consolidated view of operational updates, financial developments, capital structure changes, and strategic decisions affecting Prenetics and its IM8 brand.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Prenetics Global Limited (NASDAQ: PRE) announced its fourth quarter and full year 2022 financial results, reporting a revenue of US$275.8 million for 2022 and US$52.3 million for Q4 2022, reflecting a 19.2% decrease year-over-year. The Company achieved an adjusted EBITDA of US$58.3 million for 2022. Notably, Prenetics is shifting focus to precision oncology, highlighted by the acquisition of ACT Genomics, the first Asian firm to receive FDA clearance for its genomic profiling test. The Company aims to implement a US$20 million share buy-back program while also reducing its workforce by 60% to streamline operations and cut costs.
Prenetics Global Limited (NASDAQ: PRE) has announced the formation of a new Scientific Advisory Board (SAB) aimed at enhancing its diagnostic cancer genomics platform. The SAB comprises respected experts in oncology and genomics, including Prof. Tony Mok, who will chair the board. This strategic move is designed to leverage their expertise for advancing precision oncology, particularly early cancer detection. CEO Danny Yeung emphasized the significance of these appointments in driving innovative solutions for cancer treatment. Prenetics continues to focus on its goal of transforming patient care through advanced genomic technologies.